Phaseline

Targets › GNAO1

GNAO1 (Guanine nucleotide-binding protein G(o) subunit alpha): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Dec 2026.

Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signaling cascades, such as regulation of postsynaptic neurotransmitter release. The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state. (UniProt, P09471)

Open in Phaseline: the race on GNAO1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Pirogov Russian National Research Medical UniversityASO-GNAO1 (Tianasen)
Antisense oligonucleotide targeting GNAO1
GNAO1Phase 1GNAO1Dec 2026

Conditions

GNAO1 (1)

Modalities

other (1)

Companies

Pirogov Russian National Research Medical University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.